Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Review article: Description and management of fatigue in inflammatory bowel disease.

Czuber-Dochan W, Ream E, Norton C.

Aliment Pharmacol Ther. 2013 Mar;37(5):505-16. doi: 10.1111/apt.12205. Epub 2013 Jan 13. Review.

2.

Interventions for fatigue and weight loss in adults with advanced progressive illness.

Payne C, Wiffen PJ, Martin S.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD008427. doi: 10.1002/14651858.CD008427.pub2. Review.

PMID:
22258985
3.

Specialist nursing interventions for inflammatory bowel disease.

Belling R, McLaren S, Woods L.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006597. doi: 10.1002/14651858.CD006597.pub2. Review.

PMID:
19821376
4.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
5.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

6.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
7.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
8.

Natalizumab for induction of remission in Crohn's disease.

Macdonald JK, McDonald JW.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD006097. Review. Update in: Cochrane Database Syst Rev. 2007;(1):CD006097.

PMID:
16856112
9.

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.

Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J.

Arthritis Rheum. 2007 May 15;57(4):639-47. Review.

10.

Natalizumab for induction of remission in Crohn's disease.

MacDonald JK, McDonald JW.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD006097. Review.

PMID:
17253580
11.

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.

Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M.

Graefes Arch Clin Exp Ophthalmol. 2012 May;250(5):713-20. doi: 10.1007/s00417-011-1844-0. Epub 2011 Nov 27.

12.

[Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].

Ochsenkühn T, Sackmann M, Göke B.

Radiologe. 2003 Jan;43(1):1-8. Review. German.

PMID:
12552369
13.

Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.

Barrie A, Regueiro M.

Inflamm Bowel Dis. 2007 Nov;13(11):1424-9. Review.

PMID:
17567879
14.

Psychological interventions for treatment of inflammatory bowel disease.

Timmer A, Preiss JC, Motschall E, Rücker G, Jantschek G, Moser G.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006913. doi: 10.1002/14651858.CD006913.pub2. Review.

PMID:
21328288
15.

Mobile phone messaging for facilitating self-management of long-term illnesses.

de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD007459. doi: 10.1002/14651858.CD007459.pub2. Review.

PMID:
23235644
16.

Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease.

Pariente B, Pineton de Chambrun G, Krzysiek R, Desroches M, Louis G, De Cassan C, Baudry C, Gornet JM, Desreumaux P, Emilie D, Colombel JF, Allez M.

Inflamm Bowel Dis. 2012 Jul;18(7):1199-206. doi: 10.1002/ibd.21839. Epub 2011 Aug 29.

PMID:
22127789
17.

How do patients with inflammatory bowel disease want their biological therapy administered?

Allen PB, Lindsay H, Tham TC.

BMC Gastroenterol. 2010 Jan 10;10:1. doi: 10.1186/1471-230X-10-1.

18.

Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease.

Anderson JL, Edney RJ, Whelan K.

Aliment Pharmacol Ther. 2012 Sep;36(6):503-16. doi: 10.1111/j.1365-2036.2012.05220.x. Epub 2012 Jul 25. Review.

19.

The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease.

Lin MV, Blonski W, Buchner AM, Reddy KR, Lichtenstein GR.

Dig Dis Sci. 2013 Apr;58(4):1149-56. doi: 10.1007/s10620-012-2457-0. Epub 2012 Nov 20. Review.

PMID:
23179145
20.

Targets for Health Interventions for Inflammatory Bowel Disease-fatigue.

Artom M, Czuber-Dochan W, Sturt J, Norton C.

J Crohns Colitis. 2016 Jan 22. pii: jjw029. [Epub ahead of print] Review.

PMID:
26802088
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk